On April 27, 2026, Terns Pharmaceuticals announced that the FDA granted Breakthrough Therapy Designation (BTD) to its investigational oral allosteric BCR::ABL1 inhibitor, TERN-701, for adult patients with chromosome-positive chronic myeloid leukemia (Ph+CML) in the chronic phase without the T315I mutation who have failed two or more tyrosine kinase inhibitors. This milestone, disclosed via an 8-K filing, underscores promising Phase 1/2 data demonstrating notable molecular responses and tolerability. The designation accelerates TERN-701’s development pathway at a critical juncture preceding Merck’s planned $6.7 billion acquisition of Terns, positioning the company for integration within a larger oncology portfolio. While regulatory and clinical risks remain amid FDA workforce challenges, robust cash reserves support ongoing R&D investments [S3][F1].